Cancer immunotherapies that train or stimulate the inherent immunological systems to
recognize, attack, and eradicate tumor cells with minimal damage to healthy cells have …

Checkpoint blockade has formally demonstrated that reactivating anti-tumor immune
responses can regress tumors. However, this only occurs in a fraction of patients …

Investigations into the interaction between radiotherapy and the host immune system have
uncovered new mechanisms that can potentially be exploited to improve the efficacy of …

DNA-damaging agents are widely used in clinical oncology and exploit deficiencies in tumor
DNA repair. Given the expanding role of immune checkpoint blockade as a therapeutic …

Immunotherapy has emerged as an effective strategy for the prevention and treatment of a
variety of diseases, including cancer, infectious diseases, inflammatory diseases, and …

Radiotherapy induces and promotes innate and adaptive immunity in which host STING
plays an important role. However, radioresistance in irradiated tumors can also develop …

The recent success of cancer immunotherapy has demonstrated the power of the immune
system to clear tumors, generating renewed enthusiasm for identifying ways to induce …

Cancer immunotherapy by educating or stimulating patients' own immune systems to attack
cancer cells has demonstrated promising therapeutic responses in the clinic. However …

The past 20 years have seen dramatic changes in the delivery of radiation therapy, but the
impact of radiobiology on the clinic has been far less substantial. A major consideration in …

Immune checkpoint-targeted monoclonal antibodies directed at Programmed Death
Receptor 1 (PD-1), Programmed Death Ligand 1 (PD-L1) and Cytotoxic T-Lymphocyte …